Congratulate our CEO, Prof. Dr. Rösch, on his excellent “Pioneer lecture” about radionuclides in molecular imaging & therapy in the 35th International Austrian Winter Symposium 2022. In this congress Prof. Dr. Rösch presented how he developed the patented radiotheranostics based on homodimeric FAP-inhibitors from bed to bench side. Besides, he showed the latest clinical reports, that all patients at late tumor stage and failure of standard therapies showed positive response to the [177Lu]Lu-DOTAGA.(SA.FAPi)2 dimer and no adverse effects. The overall survival and quality of life are significantly increased. We are confident, that our new class of theranostics, especially the dimeric radiotherapeutics, will contribute to improved quality of patient care for a variety of tumors.
